The Antitrust Review of the Americas 2019 – Cooley M&A


High-tech antitrust enforcement is at the top of the Trump administration antitrust enforcement agenda, including challenges to mergers affecting technology platforms and the pharma and life sciences industries. Statements by senior leadership at both the US Department of Justice and US Federal Trade Commission promise vigorous enforcement in tech and pharma industries, and recent actions against transactions, including non-reportable deals, prove they are serious.

Read the article 



Source link

Leave a Reply

Your email address will not be published.

Sign In

Register

Reset Password

Please enter your username or email address, you will receive a link to create a new password via email.